A randomized placebo‐controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Issue 3 (5th January 2022)

• Record Type: Journal Article
• Authors: Cudkowicz, Merit E.; Lindborg, Stacy R.; Goyal, Namita A.; Miller, Robert G.; Burford, Matthew J.; Berry, James D.; Nicholson, Katharine A.; Mozaffar, Tahseen; Katz, Jonathan S.; Jenkins, Liberty J.; Baloh, Robert H.; Lewis, Richard A.; Staff, Nathan P.; Owegi, Margaret A.; Berry, Donald A.; Gothelf, Yael; Levy, Yossef S.; Aricha, Revital; Kern, Ralph Z.; Windebank, Anthony J.; Brown, Robert H.
• Is Part Of: Muscle & nerve. Volume 65:Issue 3(2022)
• Page Start: 291
• Page End: 302
• Publication Date: 2022-01-05
• Subjects: ALSFRS‐R -- amyotrophic lateral sclerosis -- biomarker -- clinical trial -- stem cells; Neuromuscular diseases -- Periodicals; Muscles -- Periodicals; Nerves -- Periodicals; 616.74
• DOI: 10.1002/mus.27472
• Languages: English
• ISSNs: 0148-639X

Abstract

Abstract: Introduction/Aims: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative illness with great unmet patient need. We aimed to evaluate whether mesenchymal stem cells induced to secrete high levels of neurotrophic factors (MSC‐NTF), a novel autologous cell‐therapy capable of targeting multiple pathways, could safely slow ALS disease progression. Methods: This randomized, double‐blind, placebo‐controlled study enrolled ALS participants meeting revised El Escorial criteria, revised ALS Functional Rating Scale (ALSFRS‐R) ≥25 (screening) and ≥3 ALSFRS‐R points decline prior to randomization. Participants received three treatments of MSC‐NTF or placebo intrathecally. The primary endpoint evaluated efficacy of MSC‐NTF through a responder analysis and safety. A change in disease progression post‐treatment of ≥1.25 points/mo defines a clinical response. A pre‐specified analysis leveraged baseline ALSFRS‐R of 35 as a subgroup threshold. Results: Overall, MSC‐NTF treatment was well tolerated; there were no safety concerns. Thirty‐three percent of MSC‐NTF and 28% of placebo participants met clinical response criteria at 28 wk (odds ratio [OR] = 1.33, P = .45); thus, the primary endpoint was not met. A pre‐specified analysis of participants with baseline ALSFRS‐R ≥ 35 (n = 58) showed a clinical response rate at 28 wk of 35% MSC‐NTF and 16% placebo (OR = 2.6, P = .29). Significant improvements in cerebrospinal biomarkers of neuroinflammation, neurodegeneration, and neurotrophic factor support were observed with MSC‐NTF, with placebo unchanged. Discussion: The study did not reach statistical significance on the primary endpoint. However, a pre‐specified subgroup suggests that MSC‐NTF participants with less severe disease may have retained more function compared to placebo. Given the unmet patient need, the results of this trial warrant further investigation.